Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec 2;13(12):2931-2952.
doi: 10.1080/21645515.2017.1359362. Epub 2017 Nov 7.

Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers

Inga Hochnadel  1 , Uta Kossatz-Boehlert  2 , Nils Jedicke  1 , Henrike Lenzen  1 , Michael P Manns  1 , Tetyana Yevsa  1
Affiliations
Review

Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers

Inga Hochnadel et al. Hum Vaccin Immunother. .

Abstract

Hepatobiliary and pancreatic cancers along with other gastrointestinal malignancies remain the leading cause of cancer-related deaths worldwide. Strategies developed in the recent years on immunotherapy and cancer vaccines in the setting of primary liver cancer as well as in pancreatic cancer are the scope of this review. Significance of orthotopic and autochthonous animal models which mimic and/or closely reflect human malignancies allowing for a prompt and trustworthy analysis of new therapeutics is underlined. Combinational approaches that on one hand, specifically target a defined cancer-driving pathway, and on the other hand, restore the functions of immune cells, which effector functions are often suppressed by a tumor milieu, are shown to have the strongest perspectives and future directions. Among combinational immunotherapeutic approaches a personalized- and individual cancer case-based therapy is of special importance.

Keywords: cancer vaccines; cholangiocarcinoma; gastrointestinal cancer; hepatocellular carcinoma; immunotherapy; pancreatic ductal adenocarcinoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Total numbers of clinical studies. Summary of total numbers of clinical studies in HCC, CCA and PDAC, found using the defined keywords in www.ClinicalTrials.gov and in MEDLINE/PubMed database.
See this image and copyright information in PMC

References

    1. Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, Li J, Huang K. Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract. 2016;2016:8962321. doi:10.1155/2016/8962321. PMID:26941789. - DOI - PMC - PubMed
    1. Organization, W.H.O Cancer. http://www.who.int/cancer/en/.
    1. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalance worldwide in 2012. http://globocan.iarc.fr/Default.aspx.
    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21. doi:10.1158/0008-5472.CAN-14-0155. PMID:24840647. - DOI - PubMed
    1. Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. World J Gastroenterol. 2014;20:11182–98. doi:10.3748/wjg.v20.i32.11182. PMID:25170203. - DOI - PMC - PubMed

Publication types

Substances